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Abstract: In this paper, we evaluate the closed-loop performance of two switching strategies for
a dual-hormone artificial pancreas (AP). The dual-hormone AP administers insulin and glucagon
subcutaneously. Since insulin and glucagon have opposite effects, we want to avoid simultaneous
injections of these two hormones. To handle non-simultaneous injections of insulin and glucagon,
we compare model predictive control (MPC) algorithms using a hysteresis switch between insulin
and glucagon controllers with a multiple-input single-output (MISO) formulation. Although
the closed-loop performance of these two control strategies is similar, the hysteresis switch
is preferable due to (i) its greater flexibility in control design and tuning and (ii) a more
straightforward way to avoid simultaneous injections of insulin and glucagon.
Keywords: Dual hormone artificial pancreas, diabetes technology, type 1 diabetes, model
predictive control
1. INTRODUCTION
The artificial pancreas (AP) has the potential to automat-
ically provide insulin doses for patients with T1D (Trevitt
et al. (2015); Haidar (2016)). A major concern for an AP is
safety and in particular its ability to avoid insulin-induced
hypoglycemia (low blood glucose). One way to prevent
hypoglycemia or to reduce the duration of hypoglycemic
events is to include glucagon in the AP. An AP able to
administer insulin and glucagon is referred to in this paper
as a dual-hormone AP while in other works it is referred
to as a bihormonal AP or a (bihormonal) bionic pancreas.
Current versions of the dual-hormone AP consist of a
CGM, a control algorithm, and two pumps for insulin and
glucagon administration.
Regular glucagon is not stable in an aqueous liquid formu-
lation under standard conditions and has to be dissolved
immediately before use. Therefore, its use has been limited
to hypoglycemia rescue kits. Stable liquid formulations
of glucagon or glucagon analogues have the potential to
be used in pumps (Castle et al. (2016); Zealand Pharma
- Dasiglucagon multiple-dose pump use (2018)). Results
from simulations and clinical studies show that a dual-
hormone AP can increase the safety of the glucose control
and provide tighter regulation than a single-hormone AP
without increasing the risk of hypoglycemia (Russell et al.
(2014); Haidar et al. (2017)).
The first clinical studies of the dual-hormone AP by
Russell et al. (2014) allowed simultaneous administration
of insulin and glucagon. These studies showed that a dual-
 This paper is funded by The Danish Diabetes Academy supported
by the Novo Nordisk Foundation.
hormone AP reduces the time spent in hypoglycemia,
but the total amount of administered glucagon was for
some patients higher than the rescue dose (1 mg). In this
study, a number of patients reported nausea and vomiting,
which are known side effects of an excessive glucagon
administration. In the work from Haidar et al. (2015), the
insulin delivery was suspended before delivering glucagon.
To avoid adverse effects, it is therefore crucial to design
control strategies that avoid unnecessary injections of
glucagon. In our previous work, we considered a hysteresis
switching strategy between insulin and glucagon (Ba´tora
et al. (2014); Ba´tora et al. (2015); Boiroux et al. (2015)).
MPC strategies with switching for more general appli-
cations have been theoretically studied (Bemporad and
Morari (1999); Dua et al. (2002); Mhaskar et al. (2005)).
In this paper, we consider two strategies to handle switch-
ing. The first strategy uses a hysteresis switch based on
the measured glucose concentration. The second strategy
uses a multiple input single output (MISO) formulation
where a penalty on glucagon injections reduces the risk of
simultaneous injection of insulin and glucagon.
This paper is structured as follows. Section 2 presents
the continuous-time transfer function model. Section 3
describes the optimal control problem (OCP) solved at
every time sample. In Section 4, we discuss the comparison
between the hysteresis switch of MPC and the MISO MPC
algorithms using 30-hour simulations on three virtual
patients. Section 5 summarizes the main contributions of
this paper.
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1. INTRODUCTION
The artificial pancreas (AP) has the potential to automat-
ically provide insulin doses for patients with T1D (Trevitt
et al. (2015); Haidar (2016)). A major concern for an AP is
safety and in particular its ability to avoid insulin-induced
hypoglycemia (low blood glucose). One way to prevent
hypoglycemia or to reduce the duration of hypoglycemic
events is to include glucagon in the AP. An AP able to
administer insulin and glucagon is referred to in this paper
as a dual-hormone AP while in other works it is referred
to as a bihormonal AP or a (bihormonal) bionic pancreas.
Current versions of the dual-hormone AP consist of a
CGM, a control algorithm, and two pumps for insulin and
glucagon administration.
Regular glucagon is not stable in an aqueous liquid formu-
lation under standard conditions and has to be dissolved
immediately before use. Therefore, its use has been limited
to hypoglycemia rescue kits. Stable liquid formulations
of glucagon or glucagon analogues have the potential to
be used in pumps (Castle et al. (2016); Zealand Pharma
- Dasiglucagon multiple-dose pump use (2018)). Results
from simulations and clinical studies show that a dual-
hormone AP can increase the safety of the glucose control
and provide tighter regulation than a single-hormone AP
without increasing the risk of hypoglycemia (Russell et al.
(2014); Haidar et al. (2017)).
The first clinical studies of the dual-hormone AP by
Russell et al. (2014) allowed simultaneous administration
of insulin and glucagon. These studies showed that a dual-
 This paper is funded by The Danish Diabetes Academy supported
by the Novo Nordisk Foundation.
hormone AP reduces the time spent in hypoglycemia,
but the total amount of administered glucagon was for
some patients higher than the rescue dose (1 mg). In this
study, a number of patients reported nausea and vomiting,
which are known side effects of an excessive glucagon
administration. In the work from Haidar et al. (2015), the
insulin delivery was suspended before delivering glucagon.
To avoid adverse effects, it is therefore crucial to design
control strategies that avoid unnecessary injections of
glucagon. In our previous work, we considered a hysteresis
switching strategy between insulin and glucagon (Ba´tora
et al. (2014); Ba´tora et al. (2015); Boiroux et al. (2015)).
MPC strategies with switching for more general appli-
cations have been theoretically studied (Bemporad and
Morari (1999); Dua et al. (2002); Mhaskar et al. (2005)).
In this paper, we consider two strategies to handle switch-
ing. The first strategy uses a hysteresis switch based on
the measured glucose concentration. The second strategy
uses a multiple input single output (MISO) formulation
where a penalty on glucagon injections reduces the risk of
simultaneous injection of insulin and glucagon.
This paper is structured as follows. Section 2 presents
the continuous-time transfer function model. Section 3
describes the optimal control problem (OCP) solved at
every time sample. In Section 4, we discuss the comparison
between the hysteresis switch of MPC and the MISO MPC
algorithms using 30-hour simulations on three virtual
patients. Section 5 summarizes the main contributions of
this paper.
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2. MODELING OF THE
GLUCOSE-INSULIN-GLUCAGON DYNAMICS
This section presents a control-relevant linear model for
the glucose concentration measured by a CGM. The model
is obtained through a discretization of a transfer function
model describing insulin and glucagon action on the inter-
stitial glucose concentration. The model has a determin-
istic part and a stochastic part. The deterministic part
describes the effect of subcutaneously (sc) injected insulin
and glucagon, uI(t) and uG(t), on glucose concentration.
The stochastic part describes the effect of other unknown
factors affecting the human metabolism and the interstitial
glucose concentration.
2.1 Transfer function models
We consider a continuous-time model of the form
Y (s) = YD(s) + YS(s) = G(s)U(s) +H(s)E(s). (1)
YD(s) represents the deterministic part of the model and
YS(s) the stochastic part of the model. The term YD(s) =
G(s)U(s) in (1) models the effect of the manipulated
variables, U(s) (insulin and glucagon), on the output (sc
CGM glucose concentration). Thus, the deterministic part,
YD(s), can be reformulated as







GI(s) and GG(s) represent the transfer functions from
insulin/glucagon to sc glucose. UI(s) and UG(s) are the
Laplace transforms of the insulin injection, uI(t), and the
glucagon injection, uG(t).
The term YS(s) = H(s)E(s) in (1) constitutes the stochas-
tic part of the model. A significant part of YS(s) is the
significant model-patient mismatches present in the low
order models describing the effect of sc injected insulin and
sc injected glucagon on sc glucose. While the disturbance
modelH(s) can be parametrized in continuous time, we do
not do so in this paper (Hagdrup et al. (2016)). Instead,
we identify the disturbance model in discrete-time as in
Boiroux et al. (2018).
2.2 Parameter identification
In this paper, the gains, KI [(mmol/L)/(U/min)] and KG
[(mmol/L)/(pg/min)], and the time constants, τI [min]
and τG [min], are identified by least-squares fitting of
the insulin and glucagon impulse responses. Based on our
previous work (Boiroux et al. (2015)), we choose second-




, i ∈ {I,G}. (3)
2.3 Realization, filtering and prediction
After discretization, we represent the continuous-time
transfer function model as the following discrete-time state
space model in innovation form
xk+1 = Axk +BIuI,k +BGuG,k +Kεk, (4a)
yk = Cxk + εk. (4b)
The state-space matrices (A,BI , BG,K,C) are obtained
using an observer canonical realization. The innovation of
the discrete-time state space model (4) is
εk = yk − Cxˆk|k−1, (5)
and the corresponding predictions are (Jørgensen et al.
(2011))
xˆk+1|k = Axˆk|k−1 +Buˆk|k +Kεk, (6a)
xˆk+1+j|k = Axˆk+j|k +Buˆk+j|k, j = 1, . . . , N − 1, (6b)
yˆk+j|k = Cxˆk+j|k, j = 1, . . . , N, (6c)





The innovation (5) and the predictions (6) constitute
the feedback and the predictions in the model predictive
controller described in the next section.
3. OPTIMAL CONTROL PROBLEM
At each sample time, the controller computes the insulin





s. t. xˆk+1|k = Axˆk|k−1 +BIuI; k|k+
BGuG; k|k +Kek, (7b)
yˆk+1|k = Cxˆk+1|k, (7c)
xˆk+1+j|k = Axˆk+j|k +BIuI; k+j|k+
BGuG; k+j|k, j ∈ N1, (7d)
yˆk+1+j|k = Cxˆk+1+j|k, j ∈ N1, (7e)
uI;min ≤ uI; k+j−1|k ≤ uI;max, j ∈ N0, (7f)
uG;min ≤ uG; k+j−1|k ≤ uG;max, j ∈ N0, (7g)
yˆk+j|k ≥ ymin − ηˆk+j|k, j ∈ N0, (7h)
yˆk+j|k ≤ ymax + ηˆk+j|k, j ∈ N0, (7i)
ηˆk+j|k ≥ 0, j ∈ N0, (7j)







Glucose penalty function︷ ︸︸ ︷






Regularization term︷ ︸︸ ︷
λI‖∆uI;k+j|k‖2 + λG‖uG;k+j|k‖2 . (8)
We set the maximal glucagon infusion rate, uG;max, to
a large value (7g). Compared to our previous controller
design (Ba´tora et al. (2014); Ba´tora et al. (2015); Boiroux
et al. (2015)), we penalize here the 2-norm of glucagon
injections instead of glucagon variations. This formulation
penalizes the simultaneous administration of insulin and
glucagon, and more generally avoids unnecessary glucagon
injections.
3.1 Hysteresis switch
One strategy to avoid simultaneous injections of insulin
and glucagon is based on relay switching with hysteresis.
The glucagon controller is activated when the measured
glucose concentration falls below 4.5 mmol/L (81 mg/dL).
At the same time the insulin MPC is switched off. The
insulin MPC is switched back on only after the mea-
sured glucose concentration rises above 5 mmol/L (90
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Table 1. Individualized controller parameters.
Symbol Unit Patient 1 Patient 2 Patient 3
BW kg 85.0 68.6 94.8





τI min 220 170 240
uI;b mU/min 6.0 9.7 14.5
y¯I mmol/L 5.5 5.5 5.5
yI;min mmol/L 4.0 4.0 4.0





τG min 165 120 155
y¯G mmol/L 5.0 5.0 5.0
yG;min mmol/L 4.0 4.0 4.0
yG;max mmol/L 6.0 6.0 6.0
mg/dL). When the hysteresis switch is used, the glucagon
injections, uG;k+j|k, are set to 0 in (7) when the insulin
controller is active. Conversely, we set the insulin injection
rates to −uI;b in (7) when the glucagon controller is active.
Since the insulin infusion rates are expressed in terms of
deviation variables from the steady state, this corresponds
to a shutdown of the insulin pump. For further information
about the practical implementation of the switching based
on hysteresis, the reader is referred to Ba´tora et al. (2014);
Ba´tora et al. (2015).
3.2 Mealtime bolus calculation
The insulin mealtime bolus calculation utilizes information
about the insulin-to-carbohydrate ratio, IC (U/g), and the
ingested meal size, CHO (g). We estimate the IC from
the insulin sensitivity factor and the patient’s response to
a defined amount of carbohydrates ingested. We compute
the bolus size in the following way
Bolus = CHO · IC. (9)
In some of our previous work, we showed that the optimal
insulin administration following a meal is a bolus followed
by a suspension of insulin (Boiroux et al. (2010)). Similar
results have been established for meals with low-fat con-
tent (Srinivasan et al. (2014)). In this paper, we suspend
the insulin infusion for two hours after mealtime. This
strategy is also known as a super-bolus, see eg. Rossetti
et al. (2012); Boronat et al. (2015).
4. NUMERICAL RESULTS
We test the controllers for three simulated patients using
the parameters for the glucose-insulin-glucagon simulation
model described in the Appendix. The daily meal regimen
consists of three bolused meals and two unbolused snacks.
The meal sizes are adjusted according to the body weight
of the patient. In all the simulations, we use the same CGM
noise realization for comparison purposes.
Fig. 1 shows the glucose and insulin traces for Patient
3 over a 30-hour simulation. The MISO and hysteresis
control strategies show very similar performances. It must
be pointed out that the MISO formulation has a penalty
on glucagon administration. It is used to discourage simul-
taneous injection of insulin and glucagon.
Table 2 reports the closed-loop performance of the two
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Fig. 1. Simulated closed-loop performance comparison of
two different dual-hormone APs for Patient 3. From
top to bottom: Hysteresis - nominal insulin sensitiv-
ity, MISO - nominal insulin sensitivity, Hysteresis -
increased insulin sensitivity, MISO - increased insulin
sensitivity.
case where the insulin sensitivity is not increased, we did
not observe any hypoglycemia (BG≤3.9 mmol/L). For the
case where the insulin sensitivity is increased by 50%, the
MISO control strategy shows a marginally better perfor-
mance compared to the hysteresis switching strategy for 2
out of the 3 patients. For Patient 3, the hysteresis switch
showed less severe hypoglycemia (BG≤3.3 mmol/L) than
the MISO control strategy. This is possibly due to the
ability to administer glucagon sufficiently in advance of a
predicted hypoglycemic event. In summary, the switching
strategy based on hysteresis uses less insulin and glucagon
than the MISO control design in every case for a compa-
rable performance.
A switching strategy between the insulin and glucagon
controller is more flexible than the MISO controller design.
It allows different administration strategies, for instance
an insulin pump combined with a glucagon pen (Reiter
et al. (2016)) or different control algorithms for insulin
and glucagon such as in Castle et al. (2010); Russell
et al. (2012). It is also possible to design different MPC
strategies for insulin and glucagon, including different
models, glucose setpoints, or different thresholds for soft
constraints.
However, the model does not take into account the in-
hibitory action of insulin on glucagon secretion. High
insulin-on-board levels reduce the effectiveness of admin-
istered glucagon (El Youssef et al. (2014)). Some other
physiological models, including the model developed by
Man et al. (2014) and the more recent model developed by
Wendt et al. (2016, 2017), take this into account. There-
fore, larger in silico and clinical studies will be needed to
further design dual-hormone control strategies.
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case where the insulin sensitivity is not increased, we did
not observe any hypoglycemia (BG≤3.9 mmol/L). For the
case where the insulin sensitivity is increased by 50%, the
MISO control strategy shows a marginally better perfor-
mance compared to the hysteresis switching strategy for 2
out of the 3 patients. For Patient 3, the hysteresis switch
showed less severe hypoglycemia (BG≤3.3 mmol/L) than
the MISO control strategy. This is possibly due to the
ability to administer glucagon sufficiently in advance of a
predicted hypoglycemic event. In summary, the switching
strategy based on hysteresis uses less insulin and glucagon
than the MISO control design in every case for a compa-
rable performance.
A switching strategy between the insulin and glucagon
controller is more flexible than the MISO controller design.
It allows different administration strategies, for instance
an insulin pump combined with a glucagon pen (Reiter
et al. (2016)) or different control algorithms for insulin
and glucagon such as in Castle et al. (2010); Russell
et al. (2012). It is also possible to design different MPC
strategies for insulin and glucagon, including different
models, glucose setpoints, or different thresholds for soft
constraints.
However, the model does not take into account the in-
hibitory action of insulin on glucagon secretion. High
insulin-on-board levels reduce the effectiveness of admin-
istered glucagon (El Youssef et al. (2014)). Some other
physiological models, including the model developed by
Man et al. (2014) and the more recent model developed by
Wendt et al. (2016, 2017), take this into account. There-
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further design dual-hormone control strategies.
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Table 2. Percentage of time spent in different glucose ranges, administered basal insulin and
glucagon.
Nominal insulin sensitivity Insulin sensitivity increased by 50%
MISO Hysteresis MISO Hysteresis
Patient 1 G > 10.0 mmol/L (%) 0.00 0.00 0.00 0.00
3.9 ≤ G ≤ 10.0 mmol/L (%) 100.0 100.0 96.7 94.7
3.9 ≤ G ≤ 7.8 mmol/L (%) 90.8 90.6 91.1 89.7
G < 3.9 mmol/L (%) 0.00 0.00 3.3 5.3
G < 3.3 mmol/L (%) 0.00 0.00 0.00 0.00
G < 2.8 mmol/L (%) 0.00 0.00 0.00 0.00
Total basal insulin administered (U) 7.1 5.85 6.6 4.9
Total glucagon administered (µg) 64.9 31.4 148.5 93.4
Patient 2 G > 10.0 mmol/L (%) 0.00 0.00 0.00 0.00
3.9 ≤ G ≤ 10.0 mmol/L (%) 100.0 100.0 91.1 90.8
3.9 ≤ G ≤ 7.8 mmol/L (%) 92.2 92.2 86.7 86.1
G < 3.9 mmol/L (%) 0.00 0.00 8.9 9.2
G < 3.3 mmol/L (%) 0.00 0.00 0.00 1.9
G < 2.8 mmol/L (%) 0.00 0.00 0.00 0.00
Total basal insulin administered (U) 8.6 7.4 8.4 6.6
Total glucagon administered (µg) 52.0 31.0 133.1 106.1
Patient 3 G > 10.0 mmol/L (%) 0.00 0.00 3.1 4.4
3.9 ≤ G ≤ 10.0 mmol/L (%) 100.0 100.0 87.5 84.2
3.9 ≤ G ≤ 7.8 mmol/L (%) 87.2 86.4 81.1 78.9
G < 3.9 mmol/L (%) 0.00 0.00 9.4 11.4
G < 3.3 mmol/L (%) 0.00 0.00 2.5 1.9
G < 2.8 mmol/L (%) 0.00 0.00 0.00 0.00
Total basal insulin administered (U) 19.2 18.0 16.8 16.6
Total glucagon administered (µg) 121.3 99.2 219.8 207.9
5. CONCLUSION
This paper provides a comparison between switching
strategies for a dual-hormone AP. The numerical results
suggest that the closed-loop performance of a hysteresis
switching strategy and a MISO control design is similar.
However, the MISO control design has several drawbacks.
The main drawback of MISO control design is the lack of
flexibility in design. It is also more difficult to completely
avoid simultaneous injections of insulin and glucagon using
a MISO design. The results presented in this paper could
also apply to other applications where switching between
several inputs may occur. Generally, simple switching
strategies can be implemented without compromizing the
performance of the control algorithm.
Appendix A. SIMULATION MODEL
The model proposed by Herrero et al. (2013) has been used
for all the simulations in this paper. This model simulates
the effects of meals intake, subcutaneously administered
insulin and glucagon. We added the CGM model from
Breton and Kovatchev (2008).
A.1 Extended model of glucose dynamics
The glucose dynamics are described by the following
system of differential equations




X˙(t) = −p2X(t) + p2SI [I(t)− Ib], (A.1b)
Y˙ (t) = −p3Y (t) + p3SN [N(t)−Nb], (A.1c)
where G(t) [mg/dL] is the plasma glucose concentration,
I(t) [µU/dL] is the plasma insulin, and N(t) [pg/dL]
is the plasma glucagon concentration. X(t) [min−1] and
Y (t) [min−1] represent the insulin and glucagon action on
glucose production. SG [min
−1] is the fractional glucose ef-
fectiveness describing how glucose per se promotes its own
disposal and inhibits its production. SI [min
−1/(µU/mL)]
and SN [min
−1/(pg/mL)] are the insulin and glucagon
sensitivities. p2 [min
−1] and p3 [min−1] are inverses of time
constants describing the dynamics of insulin and glucagon
action. V [dL/kg] is the glucose distribution volume and
Ra(t) = D2(t)/tG [mg/min/kg] is the rate of appearance of
glucose in plasma following a meal ingestion. The subscript
b denotes basal states.
A.2 Gastrointestinal absorption model
The model incorporates the two-compartment gastroin-
testinal absorption subsystem from Hovorka et al. (2004)







D1(t) [mg/kg] describes the glucose in the first compart-
ment and D2(t) [mg/kg] is the glucose in the second
compartment. AG [-] is the carbohydrate bioavailability.
DG [mg/kg/min] represents the intake of carbohydrates
per kg of body weight.
A.3 Subcutaneous insulin absorption model
The model employs a linear model of subcutaneous insulin
absorption
I˙(t) = −keI(t) + S2(t)
VItI
, (A.3a)








−1] describes the insulin clearance from
plasma, u1 [µU/kg/min] is the subcutaneous insulin infu-
sion rate, VI [mL/kg] is the distribution volume of plasma
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insulin, and tI [min] is the insulin absorption time con-
stant. S1(t) [µU/kg] and S2(t) [µU/kg] represent a two-
compartment absorption model of subcutaneously admin-
istered insulin.
A.4 Subcutaneous glucagon absorption model
Herrero et al. use the same model structure as in case of
insulin to model the subcutaneous glucagon absorption
N˙(t) = −kNN(t) + Z2(t)
VN tN
, (A.4a)







u2(t) [pg/kg/min] is the glucagon infusion rate per body
weight. Z1(t) [pg/kg] and Z2(t) [pg/kg] represent a two-
compartment absorption of subcutaneously administered
glucagon.
A.5 Model parameters
In our simulations, we use separate sets of time-varying
parameters originally identified from 3 patients to repro-
duce the circadian rhythm. Three time windows, where
each time window contains a major meal (breakfast, lunch
or dinner), are considered: 18:00 - 05:00, 05:00 - 12:00, and
12:00 - 18:00. The following parameters vary between the
three considered time windows: The insulin sensitivity, SI ,
the glucagon sensitivity, SN , the time constant, tG, and
the two parameters, p2 and p3. We use the model together
with the identified time-varying parameters to compare
the performance of the different prediction models.
A.6 Glucose measurement
A CGM provides measurements to the controller. The
sensor measures glucose concentration in the interstitial
tissue, which differs from the glucose concentration in the
plasma. We use a model that relates the plasma glucose
concentration, G [mg/dL], to the interstitial glucose con-
centration, Gsub [mg/dL], and a non-Gaussian noise model
to simulate noise in the signal from the CGM. Hence, the
model to describe the CGM signal consists of two parts.
The first part describes the transport of glucose in the








Gsub(t) is the interstitial glucose concentration and G(t)
is the blood glucose concentration. The time constant,
τsub, is associated with glucose transport from blood to
interstitial tissues.
The second part of the model to describe the CGM signal
is the non-Gaussian sensor noise. This part of the model
is given by
ek = 0.7(ek−1 + vk), k ≥ 1, (A.6a)
vk ∼ Niid(0, 1), (A.6b)






Table A.1. Parameters of the insulin and
glucagon absorption.
Parameter Patient 1 Patient 2 Patient 3
ke (min−1) 0.1300 0.1300 0.1500
tI (min) 59.178 74.900 71.496
VI (ml/kg) 124.92 71.210 121.80
Ib (µU/ml) 8.6935 15.274 8.3832
kN (min
−1) 0.2000 0.2141 0.3771
tN (min) 30.274 14.850 19.795
VN (ml/kg) 255.11 250.00 230.67
Nb (pg/ml) 47.465 48.298 59.391
and the initial condition e0 ∼ Niid(0, 1). The parameters
are listed in Breton and Kovatchev (2008).
The glucose value, GCGM [mg/dL], returned by the sc
CGM that is used for the controller feedback is
GCGM (tk) = Gsub(tk) + ηk. (A.7)
A.7 Parameters of the simulation model
Upon a consultation with the authors, the simulation
model parameters presented in Herrero et al. (2013) have
been reidentified due to very small distribution volumes
in the original paper as reported in Table A.1. The
parameters SG = 0.014 min
−1, V = 1.7 dl/kg and Ag =
0.9 remain the same as in Herrero et al. (2013).
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